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The cellular phenotypes and the expression of cytokines were studied in the lungs of mice, using
immunohistochemistry, during different phases of slowly progressive primary murine tuberculosis infection.
During the ®rst phase the small focal lesions in healthy mice contained predominantly interleukin-2 (IL-2)-
expressing cells. A small number of tumour necrosis factor-a (TNF-a)-, monocyte chemoattractant protein-1
(MCP-1)- and IL-10-expressing cells were also present. IL-4-expressing cells were not detected. During the
second phase the mice became unwell, but the bacterial counts and the size of focal lesions stabilized. IL-4-
expressing cells appeared. The IL-10-, TNF-a- and MCP-1-expressing cells increased in number. On
progression to phase three, the mice became seriously unwell and died rapidly. The in¯ammation spread to
< 80% of the lung parenchyma. There was a marked increase in the number of IL-10-expressing cells.
Expression of other cytokines was similar to that observed in the second phase. In the lesions, 3±6% of the
macrophages (Mf) containing mycobacterial antigens expressed high levels of IL-10 and TNF-a. The
absolute numbers of CD3-, CD4- and CD11b-expressing cells in the lesions increased with the progression of
infection. The numbers of CD8 cells were reduced in the last phase of infection. The kinetics of
T-lymphocyte subsets and the pattern of cytokine expression changed with the type and degree of tissue
injury. The small number of Mf with a heavy load of mycobacterial antigens may be the cause of this
disturbance in cytokine balance, thus leading to progression of in¯ammation.
Tehmina Mustafa, Center for International Health, Armauer Hansen Building, Haukeland University
Hospital, N-5021 Bergen, Norway
INTRODUCTION
Acquired resistance to Mycobacterium tuberculosis infection is
believed to depend upon cell-mediated immunity, with major
effectors being mononuclear phagocytes and T lymphocytes [1,
2]. The immune response, however, contributes both to control of
infection and tissue damage. In murine tuberculosis (TB), both
CD4 [3, 4] and CD8 [3±6] T cells play a major role in
protective immunity. The T helper 1 (Th1) cytokines ÿ inter-
leukin (IL)-2 and interferon-g (IFN-g) ÿ promote cellular
immunity by activating macrophages (Mf), while T helper 2
(Th2) cytokines (IL-4, ÿ5, ÿ6 and ÿ10) induce B-cell differ-
entiation and promote humoral immunity [7]. Th2 cytokines are
known to down-regulate the Th1 response to a number of micro-
bial pathogens, consequently preventing infection from being
resolved [8±10]. During the ®rst 3±4 weeks of M. tuberculosis
infection, it has been shown that mice predominantly generate
a Th1 response, whereas in the following weeks they also
generate a Th2 response. This is interpreted as evidence that
the Th1 cells are protective, whereas the Th2 cells are associated
with the chronic and progressive disease [11, 12]. In human TB
the presence of an increased level of Th2 cytokines in blood is
shown to be associated with severe disease [13, 14]. A Th2-
dominated immune response has been found in tuberculin-
negative patients as compared with tuberculin-positive patients
or healthy donors [15]. In leprosy, the Th1 cytokines are
correlated with the tuberculoid form of disease while Th2
cytokines dominate in the lepromatous form [16].
We have previously established a mouse model of slowly
progressive primary tuberculosis [17, 18]. Mice infected intra-
peritoneally (i.p.) with a moderate dose of M. tuberculosis strain
H37Rv developed slowly progressive disease, which passed
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through three distinctive phases [17]. The ®rst phase was
characterized by lack of clinical signs of disease, small granulo-
mas in the lungs and progressive increase in bacterial counts.
During the second phase, mice developed signs of disease. The
bacterial counts and granuloma size, however, remained stable.
The third phase was characterized by severe disease, high
mortality and a sudden loss of the focal nature of the lesions
and spread of in¯ammatory in®ltrates to about 80% of lung
parenchyma. This dramatic deterioration took place without
signi®cant change in the bacterial counts. Thus, the increase in
morbidity and mortality appears to occur as a result of sudden
changes in the host immune response.
The aim of this study was to analyse the composition of
in¯ammatory cells and the cytokine pro®le in situ in the lungs
throughout the course of infection, with particular emphasis on
the immunological changes coinciding with a shift to different
phases of infection.
MATERIALS AND METHODS
Mouse model. The mouse model for slowly progressive primary tuber-
culosis has been described previously [17]. Brie¯y, B6D2F1Bom hybrid
female mice of approximately 12 weeks of age were used. Each mouse
was inoculated i.p. with 200 ml of phosphate-buffered saline (PBS)
containing < 1.5 ´ 106 colony-forming units (CFU) of M. tuberculosis
strain H37Rv. Mice were killed at four-weekly intervals up to week 41
and later at 52, 57 and 70 weeks after infection. Time-points selected for
this study were weeks 8 and 12 from phase 1, weeks 24 and 29 from
phase 2, and weeks 41 and 70 from phase 3.
Immunohistochemistry. One-half of a lung from each mouse was
frozen in isopentane prechilled with liquid nitrogen. From week 29
onwards, perfusion of the lungs was performed, followed by ®xation.
The right lungs were perfused with a mixture (1 : 1, vol/vol) of distilled
water and Tissue-TekÒ (OCT compound, Leica Mikroscopi AS, Oslo,
Norway) before freezing. The frozen specimens were embedded in OCT
compound and stored at ÿ 70 8C until sectioning. Sections of approxi-
mately 5 mm were prepared, in a cryostat, from frozen tissues. All the
antibodies used are described in Table 1. The sections were stained by
using the avidin±biotin±peroxidase complex (ABC; Dako A/S,
Glostrup, Denmark), as described previously [17]. Brie¯y, the sections
were ®xed in cold acetone for 10 min. Endogenous peroxidase activity
was blocked with H2O2. Sections were also pretreated with avidin and
biotin blocking solution in order to reduce endogenous biotin staining
(Vector Laboratories, Burlingame, CA, USA). To block nonspeci®c
binding mainly by Fc receptors, incubation was carried out with
normal serum of the animal species in which the secondary antibody
was made. Sections were then incubated overnight with primary
antibody. Incubation with biotinylated secondary antibody was fol-
lowed by incubation with ABC (Dako A/S). Location of antigen was
visualized by incubating sections with H2O2 and 3-amino-9-ethylcar-
bazol-containing buffer. The sections were washed in Tris-PBS (TBS)
between incubations. The slides were slightly counter-stained with
Mayer's haematoxylin. As a negative control, 1% BSA/TBS instead of
primary antibody, and an irrelevant antibody from the same species
with the same immunoglobulin subtype as the primary antibody, were
used.
Evaluation of immunostaining. For the evaluation of immunostaining,
three to four animals were analysed at each time-point. The positively
stained cells were enumerated in a light microscope as:
(1) Percentage of stained cells as evaluated by using a ´ 40 ocular
®tted with a 0.25 ´ 0.25 mm graticule. The positively stained cells
and the total number of nucleated cells were counted for each ®eld.
For each specimen, three to ®ve ®elds were counted separately from the
in¯ammatory area and morphologically normal parenchyma.
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Table 1. Antibodies used in the immunohistochemical staining
Antibodies Speci®city Source
Rat IgG2a, KT-3 CD3 (T cells) AMS biotechnology,
Frankfurt, Germany
Rat IgG2a, k, H129.19 CD4 (T cells) PharMingen, CA, USA
Rat IgG2a, k, 53-6.7 CD8 a-chain (T cells) PharMingen, CA, USA
Rat IgG2b, M1/70.15 Macrophage CD11b Seralab, Leicestershire,
England
Rat IgG2a, S4B6 IL-2 PharMingen, CA, USA
Rat IgG2b, BVD4±1D11 IL-4 PharMingen, CA, USA
Rat IgG2b, JES5±16E3 IL-10 PharMingen, CA, USA
Hamster IgG, 5H2 MCP-1 PharMingen, CA, USA
Rabbit polyclonal TNF-a Genzyme, Mexico
Rabbit polyclonal Mycobacterial antigens Dako A/S, Denmark
(BCG antigens)
Rabbit anti-rat Secondary antibody Vector Laboratories,
Burlinghame, CA
Swine anti-rabbit Secondary antibody Dako A/S, Denmark
Mouse anti-hamster Secondary antibody PharMingen, CA, USA
BCG, M. bovis bacille Calmette±GueÂrin; IL, interleukin; MCP-1, monocyte chemo-
attractant protein-1; TNF-a, tumour necrosis factor-a.
(2) Absolute number of stained cells in the in¯ammatory lesions in the
lung section from each mouse, which was evaluated as: (average number
of stained cells in three to ®ve ®elds/area of each ®eld) ´ area of the focal
lesions in the section.
The area of the focal lesions was measured using a Leitz Dialux 22 EB
microscope with ´ 1 and ´ 10 objective lens connected to a Sony CCD
video camera and using the image processing system Videoplan (Kon-
tron Bild-analyse, Eching, Germany), as described previously [17].
Statistical analysis. The Kruskal±Wallis test for three-group compar-
isons and the Mann±Whitney U-test for two-group comparisons were
used.
RESULTS
The phenotype of mononuclear cells in the lungs during the
course of infection
Figure 1(A) shows the absolute number of CD3, CD4,
CD8 and CD11b cells in the focal lesions during the course
of infection. The low level of in¯ammatory cells corresponded to
the small focal lesions observed during phase 1. During phase 2,
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Fig. 1. In situ distribution of CD3 (r), CD4 (p),
CD8 (B), and CD11b (A) positive cells in lung
sections of mice with slowly progressive
primary tuberculosis analysed by using
immunohistochemical staining. (A) Absolute
number of stained cells in the lesions. The
number of all the in¯ammatory cells increased
as the size of the focal lesions increased except
for CD8 cells, which did not increase with
shift to phase 3.
(B) Stained cells as a percentage of all cells
in the lesions. The proportion of CD8 cells
was signi®cantly lower in phase 3 as compared
to phase 2 (P 0.003) and phase 1 (P 0.03).
The mice at week 41 were moribund (dying
mice). At week 70 they constituted a selected
population of late survivors owing to natural
loss of all the moribund mice. The percentage
of CD3 cells in dying mice at week 41 was
low as compared to the late survivors at week
70 (P 0.03).
(C) Stained cells as a percentage of all cells
in the morphologically normal lung
parenchyma. The proportion of CD11b cells
was signi®cantly lower in phase 3 as compared
to phase 2 (P 0.003).
In each group, n 3 or n 4 mice except for
normal parenchyma (C) where the number of
mice in each group varied from two to seven.
Bars represent standard error of the mean
(SEM).
Table 2. Ratios of the percentage of CD11b cells to CD3 cells and
CD4 to CD8 cells in the lungs of mice with slowly progressive
primary tuberculosis
Weeks after
infection CD11b/CD3 CD4/CD8
In¯ammatory lesions
Phase 1 8 0.9 1.9
12 1.7 2.1
Phase 2 24 1.3 1.6
29 1.2 1.5
Phase 3 41 1.6 6.8*
70 0.6 6.8*
Normal areas²
Phase 1 2.8 3.9
Phase 2 1.9 0.8
Phase 3 1.3 2.9
* CD4/CD8 in phase 3 versus phase 1 and phase 2, P-value  0.003.
² Morphologically normal parenchyma in infected lungs.
as the lesions became larger, the total number of all cell types
increased. With shift to phase 3, when the in¯ammatory in®l-
trates spread to about 80% of the lung parenchyma, the total
number of CD3, CD4 and CD11b cells increased but the
number of CD8 cells was largely unchanged.
Figure 1(B) shows the percentage of stained cells in the focal
lesions during the course of infection. There was no signi®cant
change in the percentage of cells in the ®rst and second phases of
infection. With the shift to phase 3, the percentage of CD8 cells
was lower than in phase 2 (P 0.003) and phase 1 (P 0.03).
The percentage of CD4 cells was at some time-points higher or
equal to the percentage of CD3 cells. This may be because CD4
molecules are expressed on some monocytes and Mf in addition
to T cells [19]. The ratio of the percentage of CD11b to CD3
cells was similar in all the phases. The ratio of CD4 to CD8
cells was similar in phases 1 and 2, while in phase 3 was
signi®cantly higher (P 0.003) (Table 2). The main change
was the reduced number of CD8 cells in the lesions in phase
3. In phase 3 at week 41, the mice were moribund, whereas mice
killed at week 70 constituted a selected population of late
survivors as all the moribund mice were lost by this time, as
described in our previous study [17]. The ratio of CD11b to
CD3 cells in the dying mice was 1.6, but in the late survivors
this ratio was reduced to 0.6 (Table 2). This difference was
mainly the result of a lower percentage of CD3 cells in the
dying mice as compared to the late survivors (P 0.03).
Figure 1(C) shows the percentage of stained cells in the
morphologically normal parenchyma of infected lungs. There
was no difference in the number of stained cells between
different phases of infection except for CD11b cells which
were signi®cantly lower in number in phase 3 as compared to
phase 2 (P 0.003). The ratios of CD11b to CD3 cells and
CD4 to CD8 cells were not signi®cantly different in different
phases of infection (Table 2).
Figure 2 shows the pattern of staining of CD3-, CD4-, CD8-
and CD11b-expressing cells. The staining was restricted to mem-
branes in the case of CD3, CD4 and CD8 cells (Fig. 2A, 2B,
2C). In the lesions, only < 20±35% of the lymphocytes
expressed CD3 molecules. Some of the lymphocyte aggregates
did not express CD3, CD4 or CD8 (Fig. 2A, 2B, 2C). These
might thus be B lymphocytes or natural killer (NK) cells. With
CD11b antiserum, both monocyte-like cells (Fig. 2D) and large
vacuolated Mf (Fig. 2E, 2F) were stained. On the monocyte-like
cells the stain was restricted to the membranes, whereas on large
vacuolated Mf the stain was also found intracellularly. The large
vacuolated Mf expressed CD11b strongly compared with the
monocyte-like cells.
Kinetics of cells expressing IL-2, IL-4, IL-10, tumour necrosis
factor-a (TNF-a) and monocyte chemoattractant protein-1
(MCP-1) in the lesions
Figure 3 shows the percentage of cells expressing IL-2, IL-4,
IL-10, TNF-a and MCP-1 in the lungs during the course of
infection. IL-2 was expressed throughout the course of infection.
In phase 1, 30±35% of the cells expressed IL-2. In phase 2 a
lower percentage of cells (< 0.06% at week 24 and < 16% at
week 29) expressed IL-2 as compared to phase 1 (P 0.002). In
phase 3, the percentage of IL-2-expressing cells was higher
(< 21±25%) compared with phase 2 (P 0.004), but not sig-
ni®cantly different from phase 1. IL-2 was expressed on cells
both in Mf and lymphocyte aggregates, while some lymphocyte
aggregates did not express IL-2 (Fig. 4A).
IL-4 was found on a very small number of cells (Fig. 4B).
During phase 1, IL-4-expressing cells were not seen (Fig. 3).
During phase 2, 0.1±0.2% of the cells expressed IL-4 (P 0.01).
With a shift to phase 3 there were no changes in the number of
IL-4-expressing cells as compared to phase 2, and were higher
compared with phase 1 (P 0.002).
IL-10 was expressed by 0.15±0.3% of cells during phase 1
(Fig. 3). In phase 2, a higher number of cells expressed IL-10
(0.6±1.2%) as compared to phase 1 (P 0.016). With the shift
to phase 3 there was a marked increase in IL-10-expressing
cells as compared to phase 2 (P 0.008) and phase 1
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Fig. 2. Lung tissue from mice with slowly
progressive primary tuberculosis showing the
staining pattern of CD3-, CD4-, CD8- and
CD11b-positive cells in the focal in¯ammatory
lesions at week 70 after infection. Frozen
sections were stained using immunoperoxidase
staining with the avidin±biotin±peroxidase
complex (ABC). (A) (´ 280) CD3 cells in the
lesion. Some lymphocyte aggregates did not stain
with CD3 (arrow). (B) (´ 280) CD4 and
(C) (´ 280) CD8 cells in the lesions. (D) (´ 106)
CD11b was expressed by monocyte-like
macrophages. The staining occurred along the
membranes. (E) (´ 106) and (F) (´ 432) Large
vacuolated macrophages express CD11b and
stain very strongly. The stain is also expressed
intra-cellularly. Lymphocyte aggregates usually
did not contain CD11b cells (arrow).
(P 0.001). IL-10 was expressed by cells both in lymphocyte
aggregates and by a small number of the vacuolated Mf in
Mf aggregates (Fig. 4D, 4E). The bronchiolar epithelial cells
and the bronchus-associated lymphoid tissue (BALT) cells also
expressed IL-10.
TNF-a was expressed by 0.02±1% of the cells during phase 1
(Fig. 3). In phase 2 a higher number of TNF-a-positive cells
(3±5%) were found compared with phase 1 (P 0.001). In
phase 3, the number of cells expressing TNF-a was not
different compared with phase 2, and higher compared with
phase 1 (P 0.002). TNF-a was expressed exclusively by cells
in the Mf aggregates (Fig. 4G, 4H). The lymphocyte aggre-
gates did not contain TNF-a-expressing cells. TNF-a and IL-10
seemed to be expressed by the same cells in the Mf aggregates
as the staining co-localized in the neighbouring sections
(Fig. 4F, 4I).
During the course of slowly progressive TB, mycobacterial
antigens were detected in only 3±6% of the Mf in the lesions, as
has been described previously [17]. Neighbouring sections
stained for TNF-a, mycobacterial antigens and IL-10 were
analysed during phase 3. Cells with high levels of mycobacterial
antigens in the Mf aggregates seemed to express high levels of
IL-10 and TNF-a (Fig. 5).
The chemokine MCP-1 was expressed during all phases of the
infection, but the number of positive cells was, in general, low,
resembling that of IL-4-positive cells (Fig. 4C). In phase 2, the
number of cells expressing MCP-1 (0.08±0.2%) increased as
compared to phase 1 (P 0.03) (Fig. 3). During phase 3, the
number of MCP-1-expressing cells did not change signi®cantly
as compared to phase 2, and were higher as compared to phase 1
(P 0.005).
DISCUSSION
The immunological pro®le was different in the different phases
of infection in mice with slowly progressive primary TB. In the
®rst phase, cells expressing Th1 cytokines dominated small focal
lesions. A high number of cells expressed IL-2, but no IL-4-
expressing cells and only a small number of IL-10-, TNF-a- and
MCP-1-expressing cells were seen. During phase 2 there was a
Th0 pattern of cytokines in the lesions. Cells expressing IL-4
appeared. The number of IL-10-expressing cells increased
slightly. The number of cells expressing TNF-a and MCP-1
also increased. There was a reduction in the number of IL-2-
expressing cells. With a shift to phase 3 there was a marked
increase in the number of IL-10-expressing cells. There was still
a predominance of IL-4, TNF-a and MCP-1, as in phase 2, and of
IL-2, as in phase 1. There was a relative reduction in the number
of CD8 cells.
During phase 1 the mice were healthy. There was a progres-
sive increase in bacterial numbers despite the predominance of
Th1 cytokines. The in¯ammatory lesions were, however, small.
TNF-a contributes to protection against M. tuberculosis infec-
tion in mice [20±23], in particular with Th1 cytokines [24].
MCP-1 is also shown to contribute less to the in¯ammation in the
granulomas with a Th1 pattern of cytokines [25]. In phase 1, IL-2,
TNF-a and MCP-1 therefore probably contribute to the granu-
loma formation and attempt to contain the infection, but are not
able to control the bacillary multiplication.
During phase 2 the mice start to show signs of illness [17]. The
host immunity controlled bacillary multiplication and pathology.
There was, however, a reduction in the number of IL-2-produ-
cing cells, as compared to phase 1, and the appearance of IL-4-
expressing cells. IL-4 belongs to the Th2 group of cytokines [7]
and has been associated with severe or chronic disease [9±16].
IL-4 has, however, also been shown to contribute to the control
of bacillary multiplication and in¯ammatory response [26±30].
It has been shown to act as a Mf-activating factor [26, 27], can
induce monocyte in®ltration in vivo [28] and multinucleated
giant cell formation in vitro [29]. Recombinant IL-4 has been
shown to bring about the arrest of M. tuberculosis multiplication
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Fig. 3. In situ distribution of cells expressing interleukin (IL)-2, IL-4,
IL-10, tumour necrosis factor-a (TNF-a) and monocyte
chemoattractant protein-1 (MCP-1) in the lesions in lung sections of
mice with slowly progressive primary tuberculosis analysed by
immunohistochemistry. In each group, n 3 or n 4 mice. Bars
indicate the SEM. Note the different scale on the y-axis for different
cytokines. In phase 2 of infection as compared to phase 1, there were
lower numbers of IL-2-expressing cells (P 0.002) and a higher
number of IL-4- (P 0.01), IL-10- (P 0.016), TNF-a- (P 0.001)
and MCP-1- (P 0.03) expressing cells. In phase 3 as compared to
phase 2 there was a signi®cant increase in numbers of IL-10-
(P 0.008) and IL-2- (P 0.004) expressing cells. Other cytokines
were not signi®cantly different from phase 2, and were signi®cantly
higher as compared to phase 1(IL-4, P 0.002; IL-10, P 0.001;
TNF-a, P 0.002; MCP-1, P 0.005) except for IL-2 which was at
the same level as in phase 1.
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Fig. 4. Lung tissue from mice with slowly
progressive primary tuberculosis showing the
staining pattern of interleukin (IL)-2-, IL-4-,
monocyte chemoattractant protein-1 (MCP-1)-,
IL-10- and tumour necrosis factor-a (TNF-a)-
positive cells in the focal in¯ammatory lesions.
Frozen sections were stained with
immunoperoxidase using the avidin±biotin±
peroxidase complex (ABC). (A) (´ 110) Mainly
lymphocytes express IL-2 (week 29 after
infection). Note some lymphocyte aggregates
without stain for IL-2 (arrow). (B) (´ 436) IL-4
was detected in a very small number of cells
(week 24). (C) (´ 436) MCP-1 was expressed by
a small number of cells, like IL-4 (week 24).
(D) (´ 110) and (E) (´ 436) IL-10 was expressed
by lymphocytes (arrows) and macrophages
(arrow heads) (week 24). Note the small
number of macrophages with very strong
expression of IL-10. (G) (´ 110) and (H) (´ 436)
TNF-a was expressed by macrophages (week
40). Note the very strongly stained
macrophages. Lymphocyte aggregates do not
contain TNF-a expressing cells (arrows).
(F) (´ 110) and (I) (´ 110) TNF-a and IL-10
seemed to be expressed by the same cells as the
staining co-localized in neighbouring sections
(week 70).
Fig. 5. Lung tissue from mice with slowly
progressive primary tuberculosis showing the
pattern of co-localization of mycobacterial
antigen (M.Ag)-containing cells with interleukin
(IL)-10-positive (A) (´ 108), (B) (´ 108) and
tumour necrosis factor-a (TNF-a)-positive
(C) (´ 60) (D) (´ 60) cells in the same areas in
focal in¯ammatory lesions (week 70 after
infection). Frozen sections were stained with
immunoperoxidase using the avidin±biotin±
peroxidase complex (ABC).
in murine bone marrow-derived Mf [30]. In phase 2 there was a
signi®cant increase in the number of TNF-a- and MCP-1-
expressing cells. The increase in the number of MCP-1-expres-
sing cells could be promoted by IL-4 [25, 31, 32]. The increase of
MCP-1 in af¯icted mice is in agreement with the results obtained
in human TB [33, 34]. MCP-1 can contribute to control of
infection by recruiting monocytes [35] and CD4 T cells [36]
to the lesions. TNF-a stimulates the antimicrobial Mf functions
[20]. It drives the delayed type hypersensitivity response by
inducing a chemokine response, leading to recruitment of Mf in
the lesions [22, 37, 38]. This restricts the infection and prevents
dissemination [38]. The mixture of IL-2, IL-4 and a small amount
of IL-10 with TNF-a and MCP-1, as seen in the present study,
thus seems to contribute to the control of bacillary multiplication
and pathology in phase 2. Increase in the level of proin¯amma-
tory cytokines seems to cause the appearance of signs of disease.
When the infection progressed to phase 3 there was an
extensive spread of in¯ammation to about 80% of the lung
parenchyma, and a sudden increase in morbidity and mortality
was found. Concomitantly there was a marked increase in the
number of IL-10-expressing cells. An increased level of IL-10 is
found to be associated with advanced human TB [13] and
pathogenesis of M. avium [39] and M. bovis bacille Calmette±
GueÂrin (BCG) [40] in mice. But how could the extensive immune
pathology in phase 3 be compatible with the suppressive effect of
IL-10 on T-cell differentiation, function and proliferation [8,
41±43]? IL-10 has been shown to cause immune stimulation
rather than inhibition in vivo in IL-10 transgenic diabetic mice
[44±46], BCG-infected mice [40] and in IL-10-transfected
tumours transplanted in mice [47]. IL-10 has also been shown
to have a direct effect on T-cell growth in in vitro systems,
particularly in concert with other cytokines [48]. The increased
level of IL-10 could thus contribute to immune pathology in
phase 3 because of its immune stimulatory functions.
There was no signi®cant change in the number of TNF-a-
expressing cells in phase 3 as compared to phase 2. The lung cells
from these mice produced high levels of IFN-g [49]. Despite the
presence of TNF-a and IFN-g, which contribute to protection
[20±22, 30], there was progression of disease. The effects of
these cytokines, to activate Mf for killing of intracellular organ-
isms, seem to be overridden by excess IL-10 [23, 40, 50±52].
IL-10 is shown to cause inactivation of TNF-a by inducing the
release of soluble TNF-receptor 2 [53]. The sustained production of
TNF-a by the infected Mf, in the face of reduced antimicrobicidal
functions of the Mf, can cause continued recruitment of in¯am-
matory cells into the lesions and consolidation of the lung tissue.
Mycobacterial antigens were detected in 3±6% of the Mf in
the lesions. These antigen-loaded cells expressed high levels of
IL-10 and TNF-a. These heavily infected Mf also expressed
large quantities of Fas ligand [54]. These Mf therefore might
eliminate Fas-expressing cytotoxic lymphocytes, protecting
themselves from being killed and thereby creating an intracel-
lular sanctuary for M. tuberculosis [54]. IL-10 is shown to have
an antiapoptotic function, causing an increase in the survival of
the cell [53, 55, 56]. These infected Mf seem to be a continuous
focus for the production of proin¯ammatory cytokines, leading
to an increased accumulation of in¯ammatory cells. The increase
in pathology seems to be the main cause of progression from
disease to mortality in the mice.
In spite of the Th0 pattern of cytokines in phases 2 and 3
and the presence of TNF-a, no necrosis was observed, except
in some of the dying mice at week 41, as described in our
previous morphological description of the model [17]. TNF-a
has been proposed as a major mediator of necrosis in M.
tuberculosis-infected tissue when Th1 cytokines are super-
imposed by Th2 cytokines [24, 57]. However, in M. tubercu-
losis-infected mice with disruptions in the principal TNF
receptor or treatment with anti-TNF-a antibody, tissue necrosis
is seen [22]. This shows that mechanisms other than TNF-a
contribute to necrosis.
Mycobacteria have evolved mechanisms to evade the phago-
lysosomal environment and probably escape to the cytoplasm
[58]. Cytotoxic CD8 cells recognize the antigens when pre-
sented with major histocompatibility complex (MHC) class I
molecules [6]. The perforin-containing cytotoxic granules in
CD8 cells can kill the bacilli directly and are important for
the containment of infection during the late stage of murine TB
[6]. The shift to phase 3 coincided with a signi®cant decrease in
the percentage of CD8 cells. This could be a result of the
change in cytokine pattern on CD8 cells as shown by some
studies. In murine schistosomiasis with a Th0 pattern of cyto-
kines, the generation of CD8 cells was found to be defective
[59]. Mature mouse CD8 cells were shown to develop into a
CD8ÿ CD4ÿ population in the presence of IL-4 [60]. In our study
the question remains whether the reduction in CD8 cells is the
cause or effect of changes in cytokine patterns.
In conclusion, the kinetics of T-lymphocyte subsets and the
pattern of cytokines produced in the lungs changed with the type
and degree of tissue injury in mice with slowly progressive
primary TB. The mixed Th1/Th2 cytokine pattern was associated
with the evolution of disease. A small number of Mf with a
heavy load of mycobacterial antigens may be the cause of this
disturbance in cytokine balance, thus leading to disease and
mortality. This model contributes to further understanding of the
factors responsible for progression of subclinical infection to
disease and to mortality.
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